As a mitotic inhibitor, it is widely used in chemotherapy to treat a variety of pathologies, including acute lymphoblastic leukemia, acute myeloid leukemia, Hodgkin's disease, neuroblastoma, and small-cell lung disease. Because of its effectiveness and mechanism of action, it is often part of a combination chemotherapy regimen and can complement other chemotherapy drugs. Vincristine is best known for its role in treating critical illnesses in children, particularly acute lymphoblastic leukemia and Hodgkin's disease. If you are interested in chemotherapy drugs, please contact Xi'an Sonwu. Xi'an Sonwu can provide you with raw 99 API vincristine powder.
|
Less than or equal to 0.001% |
Less than or equal to 0.001% |
|
|
Less than or equal to 0.0001% |
Less than or equal to 0.0001% |
|
|
4.5~6.5 |
4.5 |
|
|
Less than or equal to 3.0% |
2.7% |
|
|
Less than or equal to 2ppm |
||
|
Less than or equal to 2ppm |
||
|
Less than or equal to 0.1ppm |
||
|
Less than or equal to 2ppm |
||
|
Less than or equal to 1000cfu/g |
||
|
Less than or equal to 1000cfu/g |
||
|
98.0%~102.0% |
99.94% |
With over a decade of experience in the business, Xi'an Sonwu Biotech Co. Ltd. is an expert in producing and distributing raw materials. Xi'an Sonwu has formed solid and dependable alliances with nations in America, Asia, Europe, and Oceania. Prioritizing product quality, Xi'an Sonwu works hard to satisfy each client's expectations in full by offering top-notch services.
Xi'an Sonwu prioritizes producing high-quality goods, and all facets of its business operations, such as raw material selection, manufacturing procedures, sample testing, and staff professionalism, reflect the company's commitment to excellence. By closely observing every aspect, Xi'an Sonwu can cut costs without compromising quality and ensure that customers obtain products of exceptional value.
|
1g |
1g |
The mechanism of action of vincristine revolves around its ability to disrupt microtubule formation. A vital component of the cytoskeleton of cells, microtubules are engaged in various biological activities, including mitosis, intracellular transport, and cell shape maintenance. Microtubules are critical for chromosome segregation during the mitotic phase of the cell cycle. It functions by binding to tubulin, a significant component of microtubules. Specifically, it binds to the plus ends of tubulin dimers, preventing them from polymerizing into microtubules. This effect freezes the mitotic spindle, preventing chromosomes from segregating during metaphase. As a result, cells cannot complete mitosis, resulting in cell cycle arrest at the metaphase-anaphase boundary. The inability of cells to divide typically triggers apoptosis or programmed cell death, especially in rapidly dividing cells such as diseased cells.
It can also interfere with protein metabolism, inhibit the activity of RNA polymerase, and inhibit the synthesis of cell membrane lipids and the transport of amino acids on the cell membrane. Vincristine has a more significant inhibitory effect on transplanted diseased cells than vinblastine and has a broad anti-diseased spectrum. In addition to being effective against vinblastine-sensitive diseased strains, it is also effective against mouse Ridgeway osteosarcoma, Mecca lymphosarcoma, and X-5563 myeloma. There is no cross-resistance among vincristine, vinblastine, and vindesine, and vincristine is the most neurotoxic. After use, it is quickly distributed in various tissues. The concentration in nerve cells is high and rarely penetrates the blood-brain barrier. The cerebrospinal fluid concentration is 1/30-1/20 of the plasma concentration, and the protein binding rate is 75%. In adults, T1/2 is less than 5 minutes, T1/2 is 50-155 minutes, and the terminal elimination phase T1/2 is as long as 85 hours. It is metabolized in the liver and has the highest concentration of bile. It is mainly excreted with bile, with 70% excreted in feces and 5%-16% in urine. Vincristine can selectively concentrate in diseased tissues, synchronize proliferating cells, and enhance anti-diseased drug effectiveness.
Non-Hodgkin's Lymphoma: Vinblastine is used in treating various types of non-Hodgkin's lymphoma as part of combination therapy.
Testicular Disease: It can be used with other drugs to treat testicular disease, particularly in cases resistant to first-line treatments.
Kaposi's Sarcoma: This is a disease that causes lesions in the soft tissues, including the skin, and can be treated with vinblastine, especially in patients with AIDS-related Kaposi's sarcoma.
1. Dose-limiting toxicity is nervous system toxicity, which mainly causes peripheral nerve symptoms, such as fingers, neurotoxicity, etc. It is related to the cumulative amount-numbness of toes, slow or absent tendon reflexes, and peripheral neuritis. Occasionally, people have constipation, paralytic intestinal blockage, and abdominal pain. Damage to the cranial, motor, and sensory nerves can also result in symptoms. Neurotoxicity often occurs in people over 40 years old. Children are better tolerated than adults. Patients with malignant lymphoma are more prone to neurotoxicity than patients with other diseases.
2. Bone marrow suppression and gastrointestinal reactions are mild.
3. It has a local tissue-stimulating effect, and the liquid must not leak out. Otherwise, it may cause local necrosis.
4. Hair loss and occasional changes in blood pressure may be seen.
1. Pyrrole series antifungal agents (itraconazole) increase side effects on the muscle and nervous system. If side effects are found, appropriate treatment such as dose reduction, suspension, or medication discontinuation should be carried out. Itraconazole can inhibit the action of hepatic cytochrome P-4503A, and vincristine is metabolized by hepatocyte chromin P-4503A. Combined use can inhibit the metabolism of vincristine.
2. Combined use with phenytoin sodium may reduce the absorption of phenytoin sodium or cause hypermetabolism.
3. Combined use with platinum-containing anti-sub and malignant diseased agents may enhance the eighth pair of cranial nerve disorders.
4. Combined with L-asparaginase, it may enhance neurological and blood system disorders. It can be given 12 to 24 hours before L-asparaginase administration to reduce toxicity.
1. Xi'an Sonwu Biotech Co., Ltd. has enough inventory because it has a factory to create, make, and store the products. Xi'an Sonwu's production section is neat, orderly, and well-kept. Researchers can consistently produce novel, high-quality items under Xi'an Sonwu.
2. Xi'an Sonwu has stringent guidelines about staffing levels, ranging from sales and testing to production and testing. Rigid data support and after-sale services guarantee the entire product escorting.
For most adult diseases, the typical dosage range for it is 1.4 mg/m2 (mg per square meter of body surface area) per week. Regardless of the patient's BSA level, a maximum weekly dose limit of 2 mg is typically advised due to its neurotoxicity to reduce the risk of severe neuropathy. Smaller doses may be given more regularly in some treatment plans.
Pediatric patients' dosage is also calculated based on BSA, typically using the same weekly dose of 1.4 mg/m². However, children may have different maximum dose limits based on age and size.
If you want to know the chemotherapy vincristine manufacturer, you can contact Xi'an Sonwu. Click the email, and then you get high-quality .
sales@sonwu.com
Popularni tagovi:
